A
Anna Martínez-Cardús
Researcher at Autonomous University of Barcelona
Publications - 63
Citations - 3163
Anna Martínez-Cardús is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 28, co-authored 53 publications receiving 2443 citations.
Papers
More filters
Journal ArticleDOI
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Sebastian Moran,Anna Martínez-Cardús,Sergi Sayols,Eva Musulen,C. Balana,Anna Estival-Gonzalez,Catia Moutinho,Holger Heyn,Angel Diaz-Lagares,Manuel Castro de Moura,Giulia Maria Stella,Paolo M. Comoglio,Maria Ruiz-Miró,Xavier Matias-Guiu,Roberto Pazo-Cid,Antonio Antón,Rafael López-López,Gemma Soler,Federico Longo,Isabel Guerra,Sara Fernandez,Yassen Assenov,Christoph Plass,Rafael Morales,Joan Carles,David D.L. Bowtell,David D.L. Bowtell,Linda Mileshkin,Linda Mileshkin,Daniela Sia,Richard W. Tothill,Richard W. Tothill,Josep Tabernero,Josep M. Llovet,Manel Esteller,Manel Esteller +35 more
TL;DR: The development of a DNA methylation based assay can significantly improve diagnoses of cancer of unknown primary and guide more precise therapies associated with better outcomes.
Journal ArticleDOI
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Eva Martinez-Balibrea,Anna Martínez-Cardús,Alba Ginés,Vicenç Ruiz de Porras,Catia Moutinho,Laura Layos,Jose Luis Manzano,Cristina Buges,Sara Bystrup,Manel Esteller,Manel Esteller,Albert Abad +11 more
TL;DR: This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptosis), and epigenetic mechanisms.
Journal ArticleDOI
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano,Laura Layos,Cristina Buges,Maria de los Llanos Gil,Laia Vilà,Eva Martinez-Balibrea,Anna Martínez-Cardús +6 more
TL;DR: Mechanisms of resistance to targeted therapy and strategies to overcome them are commented on.
Journal ArticleDOI
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer.
Holger Heyn,Enrique Vidal,Humberto J. Ferreira,Miguel Vizoso,Sergi Sayols,Antonio Gomez,Sebastian Moran,Raquel Boque-Sastre,Sonia Guil,Anna Martínez-Cardús,Charles Y. Lin,Charles Y. Lin,Romina Royo,Jose V. Sanchez-Mut,Ramon Martinez,Marta Gut,David Torrents,David Torrents,Modesto Orozco,Modesto Orozco,Ivo Gut,Richard A. Young,Manel Esteller,Manel Esteller +23 more
TL;DR: In this paper, the authors used bisulfite sequencing to examine uncharted regions of the epigenome and identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers.
Journal ArticleDOI
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Michael Duruisseaux,Anna Martínez-Cardús,Maria E. Calleja-Cervantes,Sebastian Moran,Manuel Castro de Moura,Veronica Davalos,David Piñeyro,Montse Sanchez-Cespedes,Nicolas Girard,Marie Brevet,Etienne Giroux-Leprieur,Coraline Dumenil,Monica Pradotto,Paolo Bironzo,Enrica Capelletto,Silvia Novello,Alexis B. Cortot,Marie-Christine Copin,Niki Karachaliou,Maria Gonzalez-Cao,Sergio Peralta,Luis M. Montuenga,Ignacio Gil-Bazo,Iosune Baraibar,Maria D. Lozano,Mar Varela,Jose Carlos Ruffinelli,Ramon Palmero,Ernest Nadal,Teresa Moran,Lidia Perez,Immaculada Ramos,Qingyang Xiao,Agustín F. Fernández,Mario F. Fraga,Marta Gut,Ivo Gut,Cristina Teixidó,Noelia Vilariño,Aleix Prat,Noemi Reguart,Amparo Benito,Pilar Garrido,Isabel Barragan,Isabel Barragan,Jean-François Emile,Rafael Rosell,Elisabeth Brambilla,Manel Esteller +48 more
TL;DR: The epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments, and the methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade.